Innovative sprayable in situ gelling fluticasone suspension: Development and optimization of nasal deposition (CROSBI ID 264240)
Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija
Podaci o odgovornosti
Nižić, Laura ; Ugrina, Ivo ; Špoljarić, Drago ; Saršon, Vesna ; Safundžić Kučuk, Maša ; Pepić, Ivan ; Hafner, Anita
engleski
Innovative sprayable in situ gelling fluticasone suspension: Development and optimization of nasal deposition
The aim of this study was to develop an innovative in situ gelling suspension for effective nasal delivery of fluticasone. Pectin, gellan gum and sodium hyaluronate were used as gelling/thickening agents, and Tween 80 as a suspending agent. The influence of the formulation and/or administration parameters on formulation sprayability and nasal deposition was explored with an appropriate experimental design with the range for parameters in the design obtained from previous research and domain knowledge. All formulations exhibited appropriate sprayability and instant gelation upon mixing with simulated nasal fluid exhibiting weak gel properties convenient for nasal delivery. Targeted turbinate deposition depended on administration and formulation parameters, including their interactions. Decrease in the administration angle from horizontal plane, increase in inspiratory flow and presence of sodium hyaluronate significantly increased deposition in turbinate region. Parameters in interactions included concentration of polymers, surfactant and fluticasone, as well as administration angle. Selected formulations with high turbinate deposition exhibited significant increase in viscosity upon gelation, showing potential to prolong the drug retention at the nasal mucosa. The highest effect on the gel viscosity, strength and fluticasone release profile was observed for gellan gum, thus recognised as crucial parameter for the optimisation of overall therapeutic effect.
Fluticasone ; Pectin ; Gellan gum ; Sodium hyaluronate ; In situ gelling ; Nasal deposition
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
563
2019.
445-456
objavljeno
0378-5173
1873-3476
10.1016/j.ijpharm.2019.04.015